United Therapeutics (UTHR) Notes Payables (2009 - 2016)

United Therapeutics has disclosed Notes Payables across 8 years of filings, most recently posting $900000.0 for Q2 2016.

• Notes Payables for Q2 2016 came in at $900000.0, down 97.21% year-over-year; the trailing twelve-month figure through Jun 2016 was $900000.0 (down 97.21% YoY), and the FY2015 annual result was $5.4 million, down 95.73% from the prior year.
• Notes Payables came in at $900000.0 for Q2 2016 at United Therapeutics, down from $5.4 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $224.7 million in Q3 2014 to a low of $900000.0 in Q2 2016.
• The 5-year median for Notes Payables is $120.8 million (2014), against an average of $115.8 million.
• Across the five-year window, Notes Payables jumped 16619.21% in 2013 and tumbled 97.21% in 2016, its largest moves.
• United Therapeutics' Notes Payables stood at $1.3 million in 2012, then surged by 16619.21% to $215.8 million in 2013, then plunged by 41.43% to $126.4 million in 2014, then plunged by 95.73% to $5.4 million in 2015, then plunged by 83.33% to $900000.0 in 2016.
• The last three Notes Payables figures came in at $900000.0 (Q2 2016), $5.4 million (Q1 2016), and $5.4 million (Q4 2015), per Business Quant data.